Uncommon CHEK2 mis-sense variant and reduced risk of tobacco-related cancers: case–control study
Open Access
- 21 May 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 16 (15), 1794-1801
- https://doi.org/10.1093/hmg/ddm127
Abstract
CHEK2 is a key cell cycle control gene encoding a pluripotent kinase that can cause arrest or apoptosis in response to unrepaired DNA damage. We report a large case-control study of a non-functional variant that had previously been expected to increase cancer rates. Four thousand and fifteen cancer patients (2250 lung, 811 squamous upper aero-digestive and 954 kidney) and 3052 controls in central Europe were genotyped for the mis-sense variant rs17879961 (replacement of T by C), which changes an amino acid (I157T) in an active site of the gene product. The heterozygous (T/C) genotype was associated with a highly significantly lower incidence of lung cancer than the common T/T genotype [relative risk (RR), T/C versus T/T, 0.44, with 95% confidence interval (CI) 0.31–0.63, P < 0.00001] and with a significantly lower incidence of upper aero-digestive cancer (RR 0.44, CI 0.26–0.73, P = 0.001; P = 0.000001 for lung or upper aero-digestive cancer). Protection was significantly greater for squamous than adenomatous lung cancer (P = 0.001). There was an increase of borderline significance in kidney cancer (RR 1.44, CI 0.99–2.00, P = 0.06). This unexpected halving of tobacco-related cancer (since replicated independently) implies much greater absolute risk reduction in smokers than in non-smokers. The mechanism is unknown: perhaps squamous stem cell apoptosis following smoke exposure causes net harm (e.g. by forcing nearby stem cells to divide before they have repaired their own DNA damage from tobacco smoke). If so, reducing the rate of apoptosis by reducing CHEK2 activity could be protective—although not smoking would be far more so.Keywords
This publication has 19 references indexed in Scilit:
- CHEK2*1100delC and Susceptibility to Breast Cancer: A Collaborative Analysis Involving 10,860 Breast Cancer Cases and 9,065 Controls from 10 StudiesAmerican Journal of Human Genetics, 2004
- Questioning the Role of Checkpoint Kinase 2 in the p53 DNA Damage ResponsePublished by Elsevier BV ,2003
- The Chk2 Tumor Suppressor Is Not Required for p53 Responses in Human Cancer CellsPublished by Elsevier BV ,2003
- Chk1 and Chk2 kinases in checkpoint control and cancerCancer Cell, 2003
- Chk2 activates E2F-1 in response to DNA damageNature, 2003
- Mutations in CHEK2 Associated with Prostate Cancer RiskAmerican Journal of Human Genetics, 2003
- PML-dependent apoptosis after DNA damage is regulated by the checkpoint kinase hCds1/Chk2Nature, 2002
- Structural and Functional Versatility of the FHA Domain in DNA-Damage Signaling by the Tumor Suppressor Kinase Chk2Molecular Cell, 2002
- Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutationsNature Genetics, 2002
- Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni SyndromeScience, 1999